Matthew Macaluso, MD
University of Kansas School of Medicine, Wichita, Kansas
Original Research
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
August 11, 2025
Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
Original Research
Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report
July 14, 2025
History of ECT use (lifetime and current episode) or TMS use (current episode) was prognostic of poorer outcomes across the total sample and superior benefit from active versus sham...
Original Research
Utility of Combinatorial Pharmacogenomics in Depression
October 31, 2019
This study sought to ascertain the extent that pharmacogenetic testing can inform treatment decisions among patients with treatment-resistant depression whose medications are subject to gene-drug interactions—read the article to...
Article
How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example
March 19, 2015
How do you avoid drug-drug interactions in your patients who are taking multiple medications? This article explains the process for assessing the risk of a drug causing or being...
Letter to the Editor
Severe Weight Gain With Long-Acting Injectable Risperidone: A Case Report
August 12, 2010
Weight gain is a major problem with second-generation antipsychotics. Here, delve into the case of a patient diagnosed with schizophrenia, catatonic type, who gained 84 lb during 14 months...
